RedHill Biopharma Ltd. is a specialty biopharmaceutical company primarily focused on gastrointestinal infectious diseases and oncology. The company is focused on advancing its pipeline of clinical-stage therapeutic candidates while commercializing its FDA-approved product Talicia® for the treatment of H. pylori infection in adults in the United States. RedHill Biopharma identifies validates and in-licenses or acquires therapeutic candidates that align with its strategic…
RedHill Biopharma Ltd. is a specialty biopharmaceutical company primarily focused on gastrointestinal infectious diseases and oncology. The company is focused on advancing its pipeline of clinical-stage therapeutic candidates while commercializing its FDA-approved product Talicia® for the treatment of H. pylori infection in adults in the United States. RedHill Biopharma identifies validates and in-licenses or acquires therapeutic candidates that align with its strategic focus on gastrointestinal infectious diseases and oncology with the goal of becoming a leading specialty biopharmaceutical company in these therapeutic areas.
RedHill Biopharma generates revenue primarily from the commercialization of its approved product Talicia® in the United States. The company reported net revenues of approximately $7.0 million for the fiscal year ended December 31, 2024 and $6.5 million for the fiscal year ended December 31, 2023 from Talicia® sales. In addition to product sales the company has entered into licensing agreements for Talicia® in specific territories outside the United States such as the United Arab Emirates and for certain therapeutic candidates worldwide excluding North America. These agreements provide for upfront payments milestone payments and royalties on net sales contributing to the company’s revenue streams.
The company does not report operational segments based on product lines or business activities in the filing.
RedHill Biopharma operates in a competitive industry characterized by numerous pharmaceutical and biotechnology companies developing products for gastrointestinal infectious diseases and oncology. The company’s approved product Talicia® competes with branded therapies such as Pylera® and Voquezna® as well as generic versions of existing H. pylori treatments. RedHill Biopharma differentiates Talicia® through its rifabutin-based triple regimen formulation its all-in-one capsule delivery system and its activity against antibiotic-resistant strains of H. pylori. The company’s therapeutic candidates target areas with high unmet medical need such as Crohn’s disease prostate cancer and viral infections where it leverages novel mechanisms of action and seeks regulatory pathways such as the FDA’s 505(b)(2) process to enhance development efficiency.
RedHill Biopharma serves patients and healthcare providers in the United States and internationally through its commercial product and licensing arrangements. The company promotes Talicia® to physicians and patients for the treatment of H. pylori infection in adults. Through licensing partners such as Gaelan Medical in the UAE and Hyloris Pharmaceuticals for RHB-102 outside North America the company extends its reach to international markets. The customer base includes individuals suffering from gastrointestinal infectious diseases oncology patients and populations at risk from viral threats and radiation exposure.